SCHEMBL273634

SCHEMBL273634

Cc1cccc(/C=N/NC(=O)c2cc(Br)ccc2NC(=O)c2cccs2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.56
SMN1; SMN2 Q16637 6/20 0.56
POLB P06746 5/20 0.54
MAPT P10636 8/20 0.53
NPC1 O15118 8/20 0.53
NPSR1 Q6W5P4 3/20 0.53
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2D6 P10635 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
LMNA P02545 1/20 0.48
CYP3A4 P08684 1/20 0.48
HPGD P15428 2/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 5/20 0.47
MGAM O43451 1/20 0.47
SI P14410 1/20 0.47
MGAM2 Q2M2H8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266263 1.00 RAB9A (0.56) RAB9ASMN1; SMN2POLBMAPTNPC1
SCHEMBL273288 0.90 POLB (0.56) RAB9ASMN1; SMN2POLBMAPTNPC1
SCHEMBL266744 0.90 POLB (0.56) RAB9ASMN1; SMN2POLBMAPTNPC1
SCHEMBL268775 0.89 MAPT (0.54) RAB9ASMN1; SMN2POLBMAPTNPC1
SCHEMBL273459 0.89 POLB (0.54) RAB9ASMN1; SMN2POLBMAPTNPC1
SCHEMBL267036 0.89 POLB (0.54) RAB9ASMN1; SMN2POLBMAPTNPC1
SCHEMBL273641 0.89 MAPT (0.54) RAB9ASMN1; SMN2POLBMAPTNPC1
SCHEMBL273287 0.84 MAPT (0.56) RAB9ASMN1; SMN2POLBMAPTNPC1
SCHEMBL269023 0.84 MAPT (0.56) RAB9ASMN1; SMN2POLBMAPTNPC1
SCHEMBL266915 0.83 RAB9A (0.63) RAB9ASMN1; SMN2POLBMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 RAB9A 1362/4885SMN1; SMN2 4253/4885POLB 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.